Nucleic Acid Therapy Accelerator
Nucleic Acid Therapy Accelerator (NATA) is a UK-based, for-profit research hub that advances nucleic acid therapy research by providing funding, facilitating collaboration, and offering shared scientific infrastructure to academic and early-stage researchers.
- Company typePrivate
- Founded-
- HeadquartersHarwell, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Nucleic Acid Therapy Accelerator does
Nucleic Acid Therapy Accelerator (NATA) is a private, for-profit organization headquartered at the Harwell Science and Innovation Campus in the United Kingdom, focused on advancing nucleic acid therapy research. According to its own brief description, the organization operates as a research accelerator that combines three pillars: providing funding to researchers, facilitating collaboration across the field, and offering shared scientific infrastructure. The firm is positioned in a therapeutic modality space that includes antisense oligonucleotides and siRNAs, both of which are referenced in adjacent scientific literature. With 11–50 employees and a single disclosed site in Harwell, NATA is a small, specialized intermediary rather than an in-house therapeutics developer.
The organization's value proposition centers on lowering the capital and infrastructure barriers to nucleic acid therapy research — a field that typically requires specialized synthesis capabilities, screening platforms, and assay infrastructure that are costly for individual academic or early-stage groups to maintain independently. By pooling these resources and convening researchers, NATA positions itself as a coordination layer for the UK (and potentially broader European) nucleic acid therapy ecosystem. The accelerator/hub structure suggests a quasi-platform model in which participants benefit from shared capabilities, networking effects among researchers, and access to non-dilutive or catalytic funding.
The company's revenue model, pricing structure, customer segmentation, and go-to-market mechanics are not disclosed in available sources. Given the "accelerator" framing, plausible revenue sources include grant administration fees, membership or access fees for shared infrastructure, milestone or success-based payments tied to funded projects, and equity arrangements in spinouts — but none of these are confirmed in the input data. Ownership structure, investors, board composition, management team, and funding history are likewise undocumented, and the company's website returns only a Cloudflare interstitial, providing no additional disclosures. As a result, the precise commercial mechanics of NATA remain opaque from the public data set available.
Nucleic Acid Therapy Accelerator firmographics
Firmographics- Name
- Nucleic Acid Therapy Accelerator
- Website
- https://natahub.org
- Company type
- Private
- Headcount range
- 11–50 employees
- Short description
- Nucleic Acid Therapy Accelerator (NATA) is a UK-based, for-profit research hub that advances nucleic acid therapy research by providing funding, facilitating collaboration, and offering shared scientific infrastructure to academic and early-stage researchers.
- Ownership category
- akta.pro rank
Nucleic Acid Therapy Accelerator industry classification
Industry- Product category
- Biotechnology Research Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)
Keywords
Where Nucleic Acid Therapy Accelerator is headquartered
LocationHeadquarters
- HQ city
- Harwell
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Nucleic Acid Therapy Accelerator business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Nucleic Acid Therapy Accelerator product offering
Product offeringCore offering
NATA advances nucleic acid therapy research through funding, collaboration, and shared scientific infrastructure. It functions as a research accelerator supporting scientists and biotech developers working on nucleic acid-based therapeutics, providing pooled capital, collaboration channels, and shared laboratory/scientific infrastructure to advance preclinical programs.
Product overview
The available source data does not contain specific information about Nucleic Acid Therapy Accelerator's product or service offerings. The sources include a brief nature article discussing preclinical methodologies for nucleic acid therapeutics research (covering antisense oligonucleotides and siRNAs) and a placeholder webpage, but no detailed product portfolio or service descriptions for this company.
Differentiator
Problem solved
Functional benefit
Products and services
- Nucleic Acid Therapy Research Funding Funding program supporting nucleic acid therapy research and development for researchers and biotech groups working on nucleic acid-based therapeutics.
- Scientific Collaboration Program Facilitation of collaboration between researchers, academic groups, and biotech organizations working on nucleic acid-based therapeutics.
- Shared Scientific Infrastructure Shared laboratory and scientific infrastructure provided to nucleic acid therapy researchers and developers to support preclinical research activities.
Companies that use Nucleic Acid Therapy Accelerator
Customer profileIdeal customer profiles1 record
Nucleic Acid Therapy Accelerator technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Nucleic Acid Therapy Accelerator partnerships and signals
Strategic signalRecent moves1 record
Expansion highlights1 record
Nucleic Acid Therapy Accelerator competitors and assessment
Company assessmentBroad incumbents
- Alnylam Pharmaceuticals: Pioneer and leader in RNAi (siRNA) therapeutics. Comparable as the dominant siRNA platform player whose commercial success validates the modality NATA supports.
- BioNTech: Global mRNA therapeutics leader. Comparable as a major mRNA/nucleic-acid therapy player that anchors the ecosystem NATA operates in and sets scientific and commercial benchmarks.
- Ionis Pharmaceuticals: Leader in antisense oligonucleotide (ASO) therapeutics. Comparable as a foundational nucleic-acid therapy company covering the ASO modality explicitly named in NATA's research scope.
- Moderna: Global mRNA therapeutics and vaccines company. Comparable as a dominant nucleic-acid therapy incumbent that defines the modality landscape and competes for talent, capital, and partnerships.
Direct peers
- Silence Therapeutics: London-listed siRNA therapeutics developer. Comparable as a UK-headquartered nucleic-acid therapy company in the siRNA modality directly supported by NATA's mandate.
- MiNA Therapeutics: UK-based clinical-stage biotech developing RNA-based therapeutics (saRNA platform). Closely comparable as a UK-headquartered, small-team RNA therapeutics organisation operating in the same modality space NATA supports.
- CureVac: mRNA therapeutics company with broad pipeline across vaccines and protein replacement. Comparable as a pure-play nucleic-acid therapy developer operating in the same modality NATA accelerates.
Emerging players
- Arcturus Therapeutics: Clinical-stage mRNA and siRNA therapeutics developer. Comparable as a smaller, modality-focused nucleic-acid therapy peer with overlapping pipeline areas in vaccines and rare disease.
- Touchlight Genetics: UK-based DNA/RNA manufacturing platform provider. Comparable as a UK nucleic-acid infrastructure company whose enzymatic DNA offering overlaps with the upstream production needs of nucleic-acid therapy programs.
Regional players
- Medicines Discovery Catapult: UK-based life-sciences accelerator providing shared infrastructure and collaboration platforms. Comparable as a UK regional accelerator that competes with NATA for grant funding and research partnerships in translational medicine.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Nucleic Acid Therapy Accelerator social profiles
Digital presenceNucleic Acid Therapy Accelerator financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nucleic Acid Therapy Accelerator leadership team
Management profileNumber of profiles
Nucleic Acid Therapy Accelerator funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nucleic Acid Therapy Accelerator M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nucleic Acid Therapy Accelerator
What does Nucleic Acid Therapy Accelerator do?
NATA advances nucleic acid therapy research through funding, collaboration, and shared scientific infrastructure. It functions as a research accelerator supporting scientists and biotech developers working on nucleic acid-based therapeutics, providing pooled capital, collaboration channels, and shared laboratory/scientific infrastructure to advance preclinical programs.
When was Nucleic Acid Therapy Accelerator founded?
Nucleic Acid Therapy Accelerator was founded in -1. It employs 11 to 50 people.
Where is Nucleic Acid Therapy Accelerator based?
Nucleic Acid Therapy Accelerator is headquartered in Harwell, United Kingdom, in the Europe region.
Who are Nucleic Acid Therapy Accelerator's main competitors?
Broad incumbents on record are Alnylam Pharmaceuticals, BioNTech, Ionis Pharmaceuticals and Moderna. Direct peers are Silence Therapeutics, MiNA Therapeutics and CureVac. Emerging players are Arcturus Therapeutics and Touchlight Genetics. Medicines Discovery Catapult is listed as a regional player.
Does Nucleic Acid Therapy Accelerator have an API?
No public API is recorded for Nucleic Acid Therapy Accelerator.
What industry is Nucleic Acid Therapy Accelerator in?
Nucleic Acid Therapy Accelerator's product category is Biotechnology Research Services. Its primary akta.pro industry code is HLAAADAA, mRNA Therapeutics (vaccines, protein replacement, immuno-oncology). Its NAICS code is 541714 and its SIC code is 8731.